Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

8:06 AM ET 8-K
Clinical Trial Data 4D Molecular Therapeutics, Inc. FDMT

4D Molecular Therapeutics Clinical Trial Data

4D Molecular Therapeutics announced the enrollment of the first patients in its 4SIGHT Phase 3 clinical trial evaluating 4D-150 for diabetic macular edema (DME). The company also released positive 2-year data from its SPECTRA clinical trial, showing 4D-150 was well tolerated with a 61% reduction in treatment burden compared to standard aflibercept injections.

8:02 AM ET 8-K
Clinical Trial Data Keros Therapeutics, Inc. KROS

Keros Therapeutics Clinical Trial Data

Keros Therapeutics announced the dosing of the first patient in its Phase 2 clinical trial evaluating rinvatercept for the treatment of Duchenne muscular dystrophy (DMD). The open-label, multi-cohort trial will assess safety, tolerability, and functional improvements in ambulatory and non-ambulatory patients, with initial data expected in the first half of 2027.

7:03 AM ET 8-K
Clinical Trial Data Moleculin Biotech, Inc. MBRX

Moleculin Biotech Clinical Trial Data

Moleculin Biotech announced the peer-reviewed publication of a pooled cardiac safety analysis of its drug candidate Annamycin in Frontiers in Cardiovascular Medicine. The analysis of 90 patients across five clinical trials found no clinical or subclinical evidence of cardiotoxicity, even at cumulative doses exceeding traditional anthracycline limits.

Counterparty
Cleveland Clinic

“Publication of this comprehensive pooled analysis in a peer-reviewed cardiovascular medicine journal provides additional validation of the cardiac safety profile we have observed with Annamycin across our clinical development program. For decades, the clinical utility of anthracyclines has been limited by cumulative cardiotoxicity and associated lifetime dose limits. The absence of detectable cardiac toxicity in patients receiving cumulative doses of Annamycin beyond those traditional thresholds supports our continued development of Annamycin and its potential to address an important limitation of the anthracycline class.”

Walter Klemp, Chairman and Chief Executive Officer of Moleculin
1:06 PM ET 8-K
Clinical Trial Data Moleculin Biotech, Inc. MBRX

Moleculin Biotech Clinical Trial Data

Moleculin Biotech announced new preclinical data for its lead drug candidate, Annamycin, showing that its antitumor activity in pancreatic cancer is partially mediated by CD8+ T cell cytotoxicity. The findings, presented at the AACR Conference on Pancreatic Cancer, suggest the drug may turn immunologically 'cold' tumors 'hot,' potentially enabling new combination therapy approaches.

Counterparty
AACR Conference on Pancreatic Cancer
7:05 AM ET 8-K
Clinical Trial Data C4 Therapeutics, Inc. CCCC

C4 Therapeutics Clinical Trial Data

C4 Therapeutics presented new biomarker data from its Phase 1 trial of cemsidomide with dexamethasone and preliminary Phase 1b data for cemsidomide combined with elranatamab at the 23rd International Myeloma Society Annual Meeting. The data demonstrated that cemsidomide drives T-cell activation and prevents T-cell exhaustion, supporting its potential as a combination partner for immune-based therapies in relapsed/refractory multiple myeloma. Additionally, the 75 µg dose level in the Phase 1b trial was declared safe, allowing the study to advance to dose expansion and escalation cohorts.

5:11 PM ET 8-K
Clinical Trial Data Acadia Pharmaceuticals Inc ACAD

Acadia Pharmaceuticals Clinical Trial Data

Acadia Pharmaceuticals announced Phase 3 enabling topline results from the Phase 2 portion of its RADIANT trial evaluating remlifanserin for Alzheimer’s disease psychosis (ADP). While the 60 mg dose narrowly missed the primary endpoint (p=0.0603), it showed nominal significance on a key secondary endpoint and a favorable safety profile, leading the company to continue its Phase 3 program with the 60 mg dose.

Earnings call
Sep 24, 2026, 8:00 AM ET
7:31 AM ET 8-K
Clinical Trial Data Vistagen Therapeutics, Inc. VTGN

Vistagen Therapeutics Clinical Trial Data

Vistagen presented positive exploratory data at Psych Congress 2026 showing that its Phase 3 candidate fasedienol (PH94B) demonstrated statistically significant improvements in anxiety symptoms for patients with very severe social anxiety disorder. The findings, derived from post-hoc and prespecified subpopulation analyses of the PALISADE-4 and Phase 2a RDS trials, suggest that fasedienol may provide rapid-onset relief and that a second dose could further improve anticipatory anxiety.

6:02 AM ET 8-K
Clinical Trial Data Kyverna Therapeutics, Inc. KYTX

Kyverna Therapeutics Clinical Trial Data

Kyverna Therapeutics announced positive one-year topline data from its KYSA-8 registrational trial for miv-cel in stiff person syndrome (SPS) and longer-term follow-up data from its KYSA-6 trial in generalized myasthenia gravis (gMG). The results demonstrated durable clinical responses and a favorable safety profile, supporting the company's plan to complete a rolling BLA submission for SPS in Q4 2026.

Earnings call
Sep 29, 2026, 10:15 AM ET
4:12 PM ET 8-K
Clinical Trial Data Arcturus Therapeutics Holdings Inc. ARCT

Arcturus Therapeutics Holdings Clinical Trial Data

Arcturus Therapeutics released Phase 2 clinical data for ARCT-810, its mRNA-based therapeutic candidate for Ornithine Transcarbamylase (OTC) deficiency. The company also provided a strategic update on its broader mRNA delivery platform and technology pipeline.

4:06 PM ET 8-K
Clinical Trial Data Evommune, Inc. EVMN

Evommune Clinical Trial Data

Evommune announced that Phase 2a proof-of-concept data for EVO301, its IL-18 binding protein candidate for moderate-to-severe atopic dermatitis, will be presented in a late-breaking oral session at the EADV 2026 Congress. The presentation will build on topline results reported earlier in the year as the company prepares to initiate a Phase 2b dose-ranging study in mid-2027.

Counterparty
European Academy of Dermatology & Venereology (EADV)
4:02 PM ET 8-K
Clinical Trial Data Longeveron Inc. LGVN

Longeveron Clinical Trial Data

Longeveron announced that its Phase 2b ELPIS II trial evaluating laromestrocel for hypoplastic left heart syndrome (HLHS) failed to meet its primary efficacy endpoint of change in right ventricular ejection fraction at 12 months. Despite the failure, the company noted a favorable safety profile and plans to discuss exploratory clinical outcomes with the FDA to determine potential next steps. Consequently, the company has initiated cost containment measures and is exploring options to maximize shareholder value.

6:03 AM ET 8-K
Clinical Trial Data Ionis Pharmaceuticals Inc IONS

Ionis Pharmaceuticals Clinical Trial Data

Ionis and partner Roche announced positive interim results from the Phase 3 IMAgINATION study of sefaxersen in adults with IgA nephropathy (IgAN). The study met its primary endpoint, demonstrating statistically significant and clinically meaningful reductions in proteinuria compared to placebo at 37 weeks.

Counterparty
Roche Holding Ltd.

“With these positive interim results, sefaxersen is positioned to directly address a primary driver of IgAN-related kidney damage, offering the potential to help slow disease progression and potentially reduce the long-term need for dialysis or kidney transplantation.”

Brett P. Monia, Ph.D., chief executive officer, Ionis
4:23 PM ET 8-K
Clinical Trial Data Vistagen Therapeutics, Inc. VTGN

Vistagen Therapeutics Clinical Trial Data

Vistagen announced preliminary positive data from the open-label extension portion of its PALISADE-4 Phase 3 study of fasedienol for social anxiety disorder. The data showed the nasal spray was well-tolerated over 12 months of as-needed use and demonstrated clinically relevant improvements in social anxiety symptoms on both clinician-administered and patient-reported scales. The company plans to meet with the FDA this quarter to discuss the regulatory path forward for a potential New Drug Application.

Term
12 months
4:02 PM ET 8-K
Clinical Trial Data Biomea Fusion, Inc. BMEA

Biomea Fusion Clinical Trial Data

Biomea Fusion updated the anticipated timing for topline results from its Phase I GLP-131 trial of BMF-650 in obese, otherwise healthy volunteers. The company now expects to release the data in October 2026.

8:32 AM ET 8-K
Clinical Trial Data bioAffinity Technologies, Inc. BIAF

bioAffinity Technologies Clinical Trial Data

bioAffinity Technologies is presenting clinical data and research updates for its CyPath Lung diagnostic at the 2026 NAVREF Annual Conference. The presentations include clinical case studies demonstrating how the test prevents unnecessary invasive procedures and an update on the 2,000-patient FlowPath Lung longitudinal study involving veterans and military personnel.

Counterparty
National Association of Veterans’ Research and Education Foundations (NAVREF)
8:05 AM ET 8-K
Clinical Trial Data PDS Biotechnology Corp PDSB

PDS Biotechnology Clinical Trial Data

PDS Biotechnology announced the publication of Phase 2 VERSATILE-002 trial results in JAMA Oncology, evaluating PDS0101 in combination with pembrolizumab for HPV16-positive head and neck cancer. The study reported a median overall survival of 39.3 months in ICI-naïve patients, significantly exceeding the 17.9 months typically seen with standard-of-care pembrolizumab. The treatment was well-tolerated with a 13.8% rate of Grade 3 or higher treatment-related adverse events.

Counterparty
JAMA Oncology
7:09 AM ET 8-K
Clinical Trial Data Celldex Therapeutics, Inc. CLDX

Celldex Therapeutics Clinical Trial Data

Celldex reported positive topline results from its Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 trials of barzolvolimab in chronic spontaneous urticaria (CSU), meeting the primary and all key secondary endpoints. The data showed rapid and sustained efficacy through 24 weeks, including in patients refractory to omalizumab, with a favorable safety profile. The company plans to submit a Biologics License Application (BLA) to the FDA in 2027.

Earnings call
Sep 22, 2026, 8:00 AM ET

“The results from our two Phase 3 EMBARQ-CSU trials showed efficacy that is best-in-disease in CSU. We believe barzolvolimab is well-positioned to address large CSU populations of high unmet need—as a first-line therapy for patients with severe CSU or angioedema, and as the second-line advanced therapy of choice.”

Anthony Marucci, Co-Founder, President, and Chief Executive Officer at Celldex

“Barzolvolimab continued to show unprecedented complete response rates across the overall studies and demonstrated strong differentiation in patient populations underserved by existing therapies, including those with severe disease or angioedema, and those whose disease is refractory to omalizumab.”

Diane Young, MD, Senior Vice President and Chief Medical Officer of Celldex
7:06 AM ET 8-K
Clinical Trial Data Viking Therapeutics, Inc. VKTX

Viking Therapeutics Clinical Trial Data

Viking Therapeutics announced positive topline results from a maintenance study of its GLP-1/GIP agonist VK2735, demonstrating that less frequent dosing (monthly and every other week) effectively maintained weight loss. Subjects receiving weekly 17.5 mg doses achieved 22% placebo-adjusted weight loss at Week 33, and the drug showed excellent tolerability with GI adverse event rates similar to placebo during the maintenance phase.

Earnings call
Sep 29, 2026, 8:00 AM ET

“The results of our innovative maintenance dosing study continue to demonstrate the significance of VK2735’s unique and differentiated half-life and PK profile, which appear to enable an effective new approach to achieving and maintaining the weight loss goals of patients living with obesity.”

Brian Lian, Ph.D., chief executive officer of Viking

“We believe this dose-ranging study clearly demonstrated the potential viability of novel, extended dosing approaches for maintenance following induction with an incretin-based therapy.”

Brian Lian, Ph.D., chief executive officer of Viking
8:01 AM ET 8-K
Clinical Trial Data Cue Biopharma, Inc. CUE

Cue Biopharma Clinical Trial Data

Cue Biopharma announced positive topline results from a Phase 2 clinical trial of CUE-221 in patients with moderate to severe Chronic Spontaneous Urticaria (CSU). The study met its primary endpoint of complete resolution of hives (HSS7=0) at all dose levels with high statistical significance, demonstrating superiority over placebo and showing a favorable safety profile. The company plans to advance the candidate into a Phase 2b/3 registration-enabling study based on these results.

Counterparty
Genesis Life Sciences
Term
36 weeks
7:12 AM ET 8-K
Clinical Trial Data Alkermes plc. ALKS

Alkermes Clinical Trial Data

Alkermes announced positive topline results from a Phase 1b proof-of-concept study for ALKS 7290, a novel orexin 2 receptor agonist for the treatment of ADHD. The study demonstrated clinically meaningful improvements in ADHD symptoms as measured by the AISRS and CGI-S scales, marking the first clinical evidence of an orexin agonist's efficacy in ADHD. A Phase 2 study is currently enrolling with data expected in 2027.

4:03 PM ET 8-K
Clinical Trial Data Fennec Pharmaceuticals Inc. FENC

Fennec Pharmaceuticals Clinical Trial Data

Fennec Pharmaceuticals announced positive results from the investigator-initiated Phase 2 STS-J01 clinical study of PEDMARK in Japan for pediatric and AYA patients. The study met its primary endpoint, showing hearing loss in only 24.0% of patients compared to a historical benchmark of 56.4%, while demonstrating no interference with cisplatin antitumor activity.

8:31 AM ET 8-K
Clinical Trial Data Telomir Pharmaceuticals, Inc. TELO

Telomir Pharmaceuticals Clinical Trial Data

Telomir Pharmaceuticals announced the publication of peer-reviewed preclinical data in the International Journal of Molecular Sciences demonstrating that Telomir-Zn restored visual function and retinal structure in a model of age-related macular degeneration (AMD). The study showed that 14 days of oral treatment significantly improved visual performance, reduced mitochondrial oxidative stress, and increased telomeric DNA content. While the company remains focused on its Phase 1/2 clinical trial for triple-negative breast cancer, these findings suggest the drug's metal-dependent epigenetic biology may have broader applications beyond oncology.

8:55 AM ET 8-K
Clinical Trial Data Pulse Biosciences, Inc. PLSE

Pulse Biosciences Clinical Trial Data

Pulse Biosciences announced the completion of patient enrollment in its PRECISE-BTN clinical study, which evaluated the nPulse Vybrance Percutaneous Electrode System for treating symptomatic benign thyroid nodules. The study was expanded from 50 to 100 patients across three U.S. sites, and the first patient has already completed the final 12-month follow-up visit. Preliminary data is expected to be presented at an upcoming medical conference.

8:45 AM ET 8-K
Clinical Trial Data Summit Therapeutics Inc. SMMT

Summit Therapeutics Clinical Trial Data

Summit Therapeutics announced updated overall survival (OS) results from its global Phase III HARMONi trial of ivonescimab in patients with EGFR-mutated non-small cell lung cancer. The updated June 2026 analysis showed a favorable OS hazard ratio of 0.76 in the global population, demonstrating consistent efficacy across both Western and Asian patient subgroups. No new safety signals were observed, reinforcing the potential of ivonescimab as a treatment option following progression on EGFR-targeted therapy.

Counterparty
Akeso Inc.
7:30 AM ET 8-K
Clinical Trial Data BlossomHill Therapeutics, Inc. BLSM

BlossomHill Therapeutics Clinical Trial Data

BlossomHill Therapeutics announced updated Phase 1/2 SOLARA trial data for BH-30643 in patients with EGFR C797S-positive NSCLC, showing a 45% objective response rate and 88% disease control rate. The results, presented at the 2026 World Conference on Lung Cancer, demonstrate the drug's potential to overcome resistance to existing EGFR inhibitors in a population with no approved targeted therapies. The company plans to advance the candidate into a Phase 2 trial in 2027 following its recent FDA Fast Track designation.

Counterparty
International Association for the Study of Lung Cancer (IASLC)
7:07 AM ET 8-K
Clinical Trial Data Connect Biopharma Holdings Ltd CNTB

Connect Biopharma Holdings Clinical Trial Data

Connect Biopharma announced positive topline results from its global Phase 2 study of rademikibart as an add-on treatment for acute asthma exacerbations. The study met its key secondary endpoint with a statistically significant improvement in lung function (FEV1) at Day 7, and while the primary endpoint of treatment failure reduction (66%) did not reach statistical significance due to lower-than-projected event rates, the company plans to engage with the FDA for a Phase 3 program.

Earnings call
Sep 15, 2026, 8:00 AM ET
6:46 AM ET 8-K
Clinical Trial Data Vera Therapeutics, Inc. VERA

Vera Therapeutics Clinical Trial Data

Vera Therapeutics announced positive topline results from the final efficacy analysis of its Phase 3 ORIGIN 3 trial of TRUTAKNA (atacicept-vymj) in patients with IgA nephropathy. The trial met all prespecified endpoints, demonstrating a 76% reduction in the risk of kidney disease progression and stabilization of kidney function (eGFR) through 104 weeks. The company plans to submit a supplemental BLA for full FDA approval in the fourth quarter of 2026.

Term
104 weeks
4:07 PM ET 8-K
Clinical Trial Data Contineum Therapeutics, Inc. CTNM

Contineum Therapeutics Clinical Trial Data

Contineum Therapeutics reported that the Phase 2 MOONLIGHT-1 trial of JNJ-5120/PIPE-307 for major depressive disorder did not meet its primary efficacy endpoint of improvement in the MADRS total score. The drug candidate, which is being developed under a global license agreement with Johnson & Johnson, was well-tolerated with no new safety signals. Johnson & Johnson is currently evaluating the full data set, including exploratory endpoints, to determine the next steps for the program.

Counterparty
Johnson & Johnson
4:01 PM ET 8-K
Clinical Trial Data Moleculin Biotech, Inc. MBRX

Moleculin Biotech Clinical Trial Data

Moleculin Biotech announced that new data on its lead drug candidate, Annamycin (naxtarubicin), will be presented at three scientific venues in September 2026, including the AACR Conference on Pancreatic Cancer. The presentations will cover the drug's organotropism, its mechanism for targeting topoisomerase II, and its ability to stimulate CD8+ T cell cytotoxicity in pancreatic tumors. These findings support the company's broader development of Annamycin beyond its lead indication in acute myeloid leukemia (AML).

Counterparty
American Association for Cancer Research (AACR)
8:38 AM ET 8-K
Clinical Trial Data Summit Therapeutics Inc. SMMT

Summit Therapeutics Clinical Trial Data

Summit Therapeutics' partner Akeso presented updated Phase III HARMONi-2 trial data showing ivonescimab monotherapy significantly improved overall survival compared to pembrolizumab in PD-L1-positive advanced NSCLC. Ivonescimab reduced the risk of death by 27% (HR 0.73) and improved median overall survival by 8.2 months (30.8 months vs 22.6 months).

Counterparty
Akeso Inc.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.